What Makes Ligand Pharmaceuticals (LGND) an Investment Choice?

2 days ago 4

Soumya Eswaran

Wed, November 19, 2025 astatine 7:11 AM CST 3 min read

Summers Value Partners, an concern absorption company, released its third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The Summers Value Fund LP returned a nett instrumentality of 20.4% nett successful Q3 2025, surpassing the 12.4% instrumentality of the Russell 2000 Index ETF (IWM) and the 12.5% instrumentality for the Russell 2000 Value Index ETF (IWN). Year-to-date, the money is up 4.9% nett compared to 10.3% and 8.9% returns for the indexes, respectively. In addition, you tin cheque the fund’s apical 5 holdings to find retired its champion picks for 2025.

In its third-quarter 2025 capitalist letter, Summers Value Partners highlighted stocks specified arsenic Ligand Pharmaceuticals Incorporated (NASDAQ:LGND). Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is simply a biopharmaceutical institution that operates biopharmaceutical assets. The one-month instrumentality of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) was 11.58%, and its shares gained 85.60% of their worth implicit the past 52 weeks. On November 18, 2025, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) banal closed astatine $207.05 per share, with a marketplace capitalization of $4.075 billion.

Summers Value Partners stated the pursuing regarding Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) successful its 3rd 4th 2025 capitalist letter:

"Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) operates a unsocial concern exemplary wrong the pharmaceutical manufacture arsenic a royalty aggregator, requiring precise small superior to turn due to the fact that its partners money merchandise improvement and commercialization expenses. We antecedently owned BioSpecifics and Emisphere, besides pharmaceutical royalty companies. They were some acquired during our ownership generating charismatic returns for our investors.

Ligand, LGND, chemistry, test, isolated, experiment, nobody, microscopy, pharmaceutical, white, medical, pharmacology, study, laboratory, biotechnology, discovery, analysis,

Vereshchagin Dmitry/Shutterstock.com

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. According to our database, 9 hedge money portfolios held Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) astatine the extremity of the 2nd quarter, compared to 11 successful the erstwhile quarter. In the 3rd 4th of 2025, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) reported full gross and different income, connected a GAAP basis, of $115.5 million, compared to $51.8 cardinal successful Q3 2024. While we admit the imaginable of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.